Please assess the completion status of the following clinical trial:

Trial Title: To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subject (male or female) between the ages of 18 and 55 years.~* Subject with a body weight of \> 40 kg and ≤ 90 kg and a BMI between 18.0 kg/m2 and 32.0 kg/m2(both inclusive).~* Subject with a total IgE level of ≤ 100 IU/mL.~Exclusion Criteria:~* Subject has a medical history and/or current presence of disease including one or more of the allergic reaction.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CT-P39 (Part 1) (Type: EXPERIMENTAL): 150 mg/mL, Solution for injection in PFS
- EU-approved Xolair (Part 1) (Type: ACTIVE_COMPARATOR): 150 mg/mL, Solution for injection in PFS
- CT-P39 (Part 2) (Type: EXPERIMENTAL): 150 mg/mL, Solution for injection in PFS
- EU-approved Xolair (Part 2) (Type: ACTIVE_COMPARATOR): 150 mg/mL, Solution for injection in PFS
- US-licensed Xolair (Part 2) (Type: ACTIVE_COMPARATOR): 150 mg/mL, Solution for injection in PFS

Based on this trial design, predict the completion outcome and termination type (if applicable).